IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Linde, Lam Research, Marvell Technology and IDEXX Laboratories
Top Research Reports for Mastercard, Linde & Lam Research
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), Linde plc (LIN), and Lam Research Corporation (LRCX).
IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.98% and 2.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Nov 2: IDXX, STE & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers are witnessing huge market adoption of their COVID-related support products in Q3.
Idexx Laboratories (IDXX) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
If You Invested $1000 in Idexx Laboratories 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in CAG diagnostics business and the recent ezyVet buyout are likely to have contributed to growth for IDEXX (IDXX).
Idexx Laboratories (IDXX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed the most recent trading day at $651.96, moving -0.09% from the previous trading session.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Why Idexx (IDXX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle
by Zacks Equity Research
Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.
Petco (WOOF) Down 26% This Year So Far: What Should You Do?
by Zacks Equity Research
Petco (WOOF) with its omni-channel distribution and a well-diversified product offering is strongly placed in the pet care industry, which is growing rapidly.
Thermo Fisher (TMO) Launches Kit for Safer Sample Collection
by Zacks Equity Research
Thermo Fisher (TMO) launches SpeciMAX Stabilized Saliva Collection Kit that can support global efforts toward SARS-CoV-2 research by ensuring safer saliva collection.
Veeva Systems' (VEEV) New Offering to Optimize Lab Operations
by Zacks Equity Research
Veeva Systems' (VEEV) Vault LIMS is expected to help manufacturers optimize lab management and significantly simplify their systems landscape via a unified suite of quality and lab applications.